UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): May 16, 2016

                                 AMERICANN, INC.
                       -----------------------------------
             (Exact name of registrant as specified in its charter)

         Delaware                        000-54231               27-4336843
  ------------------------          -------------------      -----------------
(State or other jurisdiction       (Commission File No.)    (IRS Employer
  of incorporation)                                          Identification No.)

                          3200 Brighton Blvd., Unit 144
                                Denver, CO 80216
                  --------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (303) 862-9000


          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-14(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

                                       1
<PAGE>

Item 1.01.  Entry Into a Material Definitive Agreement

Agreements with Coastal Compassion regarding MMCC

     On April 7, 2016 the Company signed agreements with Coastal Compassion Inc.
"CCI".  CCI is one of a limited  number  of  non-profit  organizations  that has
received a provisional  or final  registration  to  cultivate,  process and sell
medical cannabis by the Massachusetts Department of Public Health.

     CCI has  agreed to become  the  initial  tenant  in the  Company's  planned
Massachusetts Medical Cannabis Center. The MMCC is approved for nearly 1,000,000
square  feet  of  medical  cannabis  cultivation  and  processing  in  Freetown,
Massachusetts.  Mr. Tim Keogh, the Company's Chief Executive Officer, is a Board
Member of CCI.

     Pursuant to the Agreements,  AmeriCann agreed to provide CCI with financing
of up to  $2.5  million  for a  five-year  term at 18%  interest  per  year  for
construction  and working  capital  required for CCI's  approved  dispensary and
cultivation  center in  Fairhaven,  MA("Fairhaven  Facility".  For a three  year
period beginning April 1, 2016,  AmeriCann has agreed to consult with CCI in the
design,  construction  and  operation of the  Fairhaven  facility.  CCI will pay
AmeriCann  $10,000  each  month  for these  consulting  services.  Although  the
Massachusetts  Department of Public  Health has approved our agreement  with CCI
relating  to the  development  and lease  terms of the MMCC,  the  actual  lease
agreement  with CCI has not been  finalized  or  approved by the  Department  of
Public Health.  Additionally,  AmeriCann will need to secure significant capital
to acquire the  property,  to develop the first phase of the MMCC project and to
provide capital to CCI to fund its loan agreement.

     The  state-of-the-art  sustainable  greenhouse MMCC project will consist of
multiple  planned  phases for  tenants in the  Massachusetts  medical  marijuana
market.  CCI finalized  agreements to occupy the first phase of the project that
consists  of  an  initial   130,000  sq.  ft.  of  cultivation   and  processing
infrastructure.  AmeriCann can expand the first phase to  approximately  600,000
sq. ft., for Coastal Compassion based on patient demand.

     The MMCC  facility  has been  designed  utilizing  AmeriCann's  proprietary
system  known  as  "Cannopy."  AmeriCann  has  drawn  on  its  team's  extensive
experience in traditional  horticulture,  lean manufacturing,  medical research,
facility construction, regulatory compliance, security, cannabis cultivation and
genetics, extraction techniques, and infused product development.

     As of May 18, 2016,  AmeriCann  had not acquired the property on which MMCC
will be built.  The purchase price for the 52.6 parcel of land on which the MMCC
will be built is  $4,225,000,  of which $675,000 has been paid. The closing date
for the purchase is June 15, 2016.

     The Company recently began funding its loan to CCI to commence construction
of the Fairhaven Facility.

                                       2
<PAGE>

Massachusetts Medical Cannabis Center

     Previously  the Company  entered  into an agreement to purchase a 52.6-acre
parcel of undeveloped land in Freetown,  Massachusetts.  The property is located
approximately  47 miles  southeast of Boston.  The Company  plans to develop the
property as the Massachusetts Medical Cannabis Center "MMCC". Plans for the MMCC
may include the construction of sustainable greenhouse cultivation,  processing,
and  infused  product  facilities  that  will be  leased  or sold to  Registered
Marijuana Dispensaries under the Massachusetts Medical Marijuana Program.

     The Company  paid the seller  $100,000  upon the  signing of the  agreement
which amount will be applied  toward the  purchase  price of  $4,000,000  at the
closing.  Pursuant to the original agreement the closing was to take place on or
before  June 1, 2015.  On May 6, 2015,  to address  site  considerations  before
finalizing  the planned  development,  the  agreement  was amended to extend the
closing date to September 1, 2015. On August 27, 2015, after addressing the site
considerations,  the agreement was amended to extend the closing date to October
30, 2015 to provide  additional  time for  permitting.  In connection  with this
amendment,  the Company paid the seller an additional  $100,000.  On October 23,
2015,  the Company made an additional  payment of $100,000 to extend the closing
date to December 29,  2015.  These  payments of $300,000  will be applied to the
purchase price.

     On December  22, 2015 the Company and the seller  amended the  agreement to
extend the closing date to February 29, 2016. As consideration for the extension
of the closing Date,  the Company  agreed to increase the purchase price for the
property to $4,100,000  and paid the seller  $100,000,  which will be applied to
the purchase price if the closing occurs.

     On February  29, 2016 the Company and the seller  amended the  agreement to
extend the closing date. As consideration for the extension of the closing date,
the Company agreed to increase the purchase price for the property to $4,150,000
and paid the seller $50,000,  which will be applied to the purchase price if the
closing occurs.

     On March 31,  2016 the  Company and the seller  amended  the  agreement  to
extend the closing date to May 16, 2016. As  consideration  for the extension of
the closing date, the Company paid the seller $75,000,  which will be applied to
the purchase price if the closing occurs.

     On May 16, 2016 the Company and Seller  amended the Agreement to extend the
closing date to June 15, 2016. As consideration for the extension of the closing
date,  the Company  agreed to increase  the  purchase  price for the property to
$4,225,000  and pay the seller  $150,000  which will be applied to the  purchase
price if the closing occurs.

     To date, the Company has paid $675,000 that will be applied to the purchase
price of the land if and when the Company closes on the transaction.

                                       3
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: May 18, 2016
                                 AMERICANN, INC.


                                 By: /s/ Timothy Keogh
                                     --------------------------------------
                                     Timothy Keogh, Chief Financial Officer
[{"type": "8-K", "sequence": "1", "filename": "form8kitem101free8amd5-16.txt", "description": "8-K ITEM 1.01", "secsgml_size_bytes": 8577}]
{"company-data": {"conformed-name": "AmeriCann, Inc.", "cik": "0001508348", "assigned-sic": "8742", "irs-number": "274336843", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54231", "film-number": "161660442"}, "business-address": {"street1": "3200 BRIGHTON BLVD.", "street2": "UNIT 114", "city": "DENVER", "state": "CO", "zip": "80216", "phone": "303-898-9832"}, "mail-address": {"street1": "3200 BRIGHTON BLVD.", "street2": "UNIT 114", "city": "DENVER", "state": "CO", "zip": "80216"}, "former-company": [{"former-conformed-name": "Americann, Inc.", "date-changed": "20140516"}, {"former-conformed-name": "Nevada Health Scan, Inc.", "date-changed": "20101220"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): May 16, 2016

                                 AMERICANN, INC.
                       -----------------------------------
             (Exact name of registrant as specified in its charter)

         Delaware                        000-54231               27-4336843
  ------------------------          -------------------      -----------------
(State or other jurisdiction       (Commission File No.)    (IRS Employer
  of incorporation)                                          Identification No.)

                          3200 Brighton Blvd., Unit 144
                                Denver, CO 80216
                  --------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (303) 862-9000

          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-14(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

                                       1
Item 1.01.  Entry Into a Material Definitive Agreement

Agreements with Coastal Compassion regarding MMCC

     On April 7, 2016 the Company signed agreements with Coastal Compassion Inc.
"CCI".  CCI is one of a limited  number  of  non-profit  organizations  that has
received a provisional  or final  registration  to  cultivate,  process and sell
medical cannabis by the Massachusetts Department of Public Health.

     CCI has  agreed to become  the  initial  tenant  in the  Company's  planned
Massachusetts Medical Cannabis Center. The MMCC is approved for nearly 1,000,000
square  feet  of  medical  cannabis  cultivation  and  processing  in  Freetown,
Massachusetts.  Mr. Tim Keogh, the Company's Chief Executive Officer, is a Board
Member of CCI.

     Pursuant to the Agreements,  AmeriCann agreed to provide CCI with financing
of up to  $2.5  million  for a  five-year  term at 18%  interest  per  year  for
construction  and working  capital  required for CCI's  approved  dispensary and
cultivation  center in  Fairhaven,  MA("Fairhaven  Facility".  For a three  year
period beginning April 1, 2016,  AmeriCann has agreed to consult with CCI in the
design,  construction  and  operation of the  Fairhaven  facility.  CCI will pay
AmeriCann  $10,000  each  month  for these  consulting  services.  Although  the
Massachusetts  Department of Public  Health has approved our agreement  with CCI
relating  to the  development  and lease  terms of the MMCC,  the  actual  lease
agreement  with CCI has not been  finalized  or  approved by the  Department  of
Public Health.  Additionally,  AmeriCann will need to secure significant capital
to acquire the  property,  to develop the first phase of the MMCC project and to
provide capital to CCI to fund its loan agreement.

     The  state-of-the-art  sustainable  greenhouse MMCC project will consist of
multiple  planned  phases for  tenants in the  Massachusetts  medical  marijuana
market.  CCI finalized  agreements to occupy the first phase of the project that
consists  of  an  initial   130,000  sq.  ft.  of  cultivation   and  processing
infrastructure.  AmeriCann can expand the first phase to  approximately  600,000
sq. ft., for Coastal Compassion based on patient demand.

     The MMCC  facility  has been  designed  utilizing  AmeriCann's  proprietary
system  known  as  "Cannopy."  AmeriCann  has  drawn  on  its  team's  extensive
experience in traditional  horticulture,  lean manufacturing,  medical research,
facility construction, regulatory compliance, security, cannabis cultivation and
genetics, extraction techniques, and infused product development.

     As of May 18, 2016,  AmeriCann  had not acquired the property on which MMCC
will be built.  The purchase price for the 52.6 parcel of land on which the MMCC
will be built is  $4,225,000,  of which $675,000 has been paid. The closing date
for the purchase is June 15, 2016.

     The Company recently began funding its loan to CCI to commence construction
of the Fairhaven Facility.

                                       2
Massachusetts Medical Cannabis Center

     Previously  the Company  entered  into an agreement to purchase a 52.6-acre
parcel of undeveloped land in Freetown,  Massachusetts.  The property is located
approximately  47 miles  southeast of Boston.  The Company  plans to develop the
property as the Massachusetts Medical Cannabis Center "MMCC". Plans for the MMCC
may include the construction of sustainable greenhouse cultivation,  processing,
and  infused  product  facilities  that  will be  leased  or sold to  Registered
Marijuana Dispensaries under the Massachusetts Medical Marijuana Program.

     The Company  paid the seller  $100,000  upon the  signing of the  agreement
which amount will be applied  toward the  purchase  price of  $4,000,000  at the
closing.  Pursuant to the original agreement the closing was to take place on or
before  June 1, 2015.  On May 6, 2015,  to address  site  considerations  before
finalizing  the planned  development,  the  agreement  was amended to extend the
closing date to September 1, 2015. On August 27, 2015, after addressing the site
considerations,  the agreement was amended to extend the closing date to October
30, 2015 to provide  additional  time for  permitting.  In connection  with this
amendment,  the Company paid the seller an additional  $100,000.  On October 23,
2015,  the Company made an additional  payment of $100,000 to extend the closing
date to December 29,  2015.  These  payments of $300,000  will be applied to the
purchase price.

     On December  22, 2015 the Company and the seller  amended the  agreement to
extend the closing date to February 29, 2016. As consideration for the extension
of the closing Date,  the Company  agreed to increase the purchase price for the
property to $4,100,000  and paid the seller  $100,000,  which will be applied to
the purchase price if the closing occurs.

     On February  29, 2016 the Company and the seller  amended the  agreement to
extend the closing date. As consideration for the extension of the closing date,
the Company agreed to increase the purchase price for the property to $4,150,000
and paid the seller $50,000,  which will be applied to the purchase price if the
closing occurs.

     On March 31,  2016 the  Company and the seller  amended  the  agreement  to
extend the closing date to May 16, 2016. As  consideration  for the extension of
the closing date, the Company paid the seller $75,000,  which will be applied to
the purchase price if the closing occurs.

     On May 16, 2016 the Company and Seller  amended the Agreement to extend the
closing date to June 15, 2016. As consideration for the extension of the closing
date,  the Company  agreed to increase  the  purchase  price for the property to
$4,225,000  and pay the seller  $150,000  which will be applied to the  purchase
price if the closing occurs.

     To date, the Company has paid $675,000 that will be applied to the purchase
price of the land if and when the Company closes on the transaction.

                                       3
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: May 18, 2016
                                 AMERICANN, INC.

                                 By: /s/ Timothy Keogh
                                     --------------------------------------
                                     Timothy Keogh, Chief Financial Officer